Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

Discover how the WHO's new guidelines on lenacapavir could revolutionise HIV prevention, offering a long-acting alternative ...

A breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

The World Health Organization (WHO) released today new guidelines recommending the use of injectable lenacapavir (LEN) twice ...

The World Health Organization (WHO) has recommended the global use of injectable lenacapavir (LEN) twice a year to provide near-total ...

Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk ...

The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its ...